Format
Sort by
Items per page

Send to

Choose Destination

Best matches for AMBRISENTAN/PD:

Ambrisentan: a review of its use in pulmonary arterial hypertension. Rivera-Lebron BN et al. Ther Adv Respir Dis. (2017)

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. Galiè N et al. N Engl J Med. (2015)

Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. Peacock AJ et al. Curr Med Res Opin. (2015)

Search results

Items: 1 to 20 of 218

1.

What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.

Li Q, Kuang HY, Wu YH, Lu TW, Yi QJ.

Medicine (Baltimore). 2019 May;98(20):e15632. doi: 10.1097/MD.0000000000015632.

2.

Role of endothelin-1 clearance in the haemodynamic responses to endothelin-1 in the pulmonary and hindquarter vasculature of anaesthetised rats.

Angus JA, Wright CE.

Eur J Pharmacol. 2019 Jul 15;855:124-136. doi: 10.1016/j.ejphar.2019.05.009. Epub 2019 May 4.

PMID:
31063771
3.

A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects.

Okour M, Puri A, Chen G, Port K, Berni A, Khindri S, Schneider I, Tenero D.

Clin Ther. 2019 Jun;41(6):1110-1127. doi: 10.1016/j.clinthera.2019.04.007. Epub 2019 May 4.

PMID:
31060740
4.

Role of ambrisentan (selective endothelin-A receptor antagonist) on cigarette smoke exposure induced cognitive impairment in Danio rerio.

Muthuraman A, Nafisa K, Sowmya MS, Arpitha BM, Choedon N, Sandy CD, Rishitha N, Johurul I.

Life Sci. 2019 Apr 1;222:133-139. doi: 10.1016/j.lfs.2019.03.002. Epub 2019 Mar 4.

PMID:
30844374
5.

Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases.

Ferguson SK, Pak DI, Hopkins JL, Harral JW, Redinius KM, Loomis Z, Stenmark KR, Borden MA, Schroeder T, Irwin DC.

Drug Deliv. 2019 Dec;26(1):147-157. doi: 10.1080/10717544.2019.1568621.

6.

A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.

Wang S, Yu M, Zheng X, Dong S.

Drug Deliv. 2018 Nov;25(1):1898-1909. doi: 10.1080/10717544.2018.1523257.

7.

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?

Correale M, Ferraretti A, Monaco I, Grazioli D, Di Biase M, Brunetti ND.

Vasc Health Risk Manag. 2018 Oct 4;14:253-264. doi: 10.2147/VHRM.S133921. eCollection 2018. Review.

8.

Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine.

Ribeiro Baptista B, Petitpain N, Gomez E, Yelehé-Okouma M, Valentin S, Guillaumot A, Chabot F, Chaouat A.

Fundam Clin Pharmacol. 2019 Feb;33(1):127-129. doi: 10.1111/fcp.12396. Epub 2018 Jul 15.

PMID:
29956855
9.

New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine.

Davenport AP, Kuc RE, Southan C, Maguire JJ.

Physiol Res. 2018 Jun 27;67(Supplementum 1):S37-S54. Review.

10.

Current and Future Treatments for Persistent Pulmonary Hypertension in the Newborn.

Pedersen J, Hedegaard ER, Simonsen U, Krüger M, Infanger M, Grimm D.

Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):392-406. doi: 10.1111/bcpt.13051. Epub 2018 Jul 19. Review.

PMID:
29855164
11.

Can results from a Japanese pulmonary hypertension registry have an impact on Western guidelines?

Tanabe N.

Respir Investig. 2018 Jul;56(4):263-264. doi: 10.1016/j.resinv.2018.02.004. Epub 2018 Mar 13. No abstract available.

PMID:
29764745
12.

A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.

Bedan M, Grimm D, Wehland M, Simonsen U, Infanger M, Krüger M.

Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):103-113. doi: 10.1111/bcpt.13033. Epub 2018 Jun 5. Review.

13.

Enhancement of solubility and bioavailability of ambrisentan by solid dispersion using Daucus carota as a drug carrier: formulation, characterization, in vitro, and in vivo study.

Deshmane S, Deshmane S, Shelke S, Biyani K.

Drug Dev Ind Pharm. 2018 Jun;44(6):1001-1011. doi: 10.1080/03639045.2018.1428339. Epub 2018 Feb 5.

PMID:
29382236
14.

Antiproteinuric effect of an endothelin-1 receptor antagonist in puromycin aminonucleoside-induced nephrosis in rat.

Kino J, Tsuji S, Kitao T, Akagawa Y, Yamanouchi S, Kimata T, Kaneko K.

Pediatr Res. 2018 May;83(5):1041-1048. doi: 10.1038/pr.2018.11. Epub 2018 Feb 21.

PMID:
29360807
15.

German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2018 Feb;72(2):155-168. doi: 10.1055/s-0043-123035. Epub 2018 Jan 16.

16.

Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).

Takahashi T, Hayata S, Kobayashi A, Onaka Y, Ebihara T, Hara T.

Clin Drug Investig. 2018 Mar;38(3):219-229. doi: 10.1007/s40261-017-0602-4.

PMID:
29282676
17.
18.

Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis.

Higa A, Hoshi H, Yanagisawa Y, Ito E, Morisawa G, Imai JI, Watanabe S, Takagi M.

J Toxicol Sci. 2017;42(6):755-761. doi: 10.2131/jts.42.755.

19.

Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies.

Grady D, Weiss M, Hernandez-Sanchez J, Pepke-Zaba J.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217743616. doi: 10.1177/2045893217743616. Epub 2017 Nov 3.

20.

Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.

Schroeder T, Piantadosi CA, Natoli MJ, Autmizguine J, Cohen-Wolkowieczs M, Hamilton KL, Bell C, Klawitter J, Christians U, Irwin DC, Noveck RJ.

Clin Pharmacol Ther. 2018 May;103(5):888-898. doi: 10.1002/cpt.860. Epub 2017 Oct 17.

Supplemental Content

Loading ...
Support Center